Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE014 (NLD) (Dr. Moreau)
· consented 2022-07-23
Adverse events
5
Serious AEs
2
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-10-05 (study day 62); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-18 (study day 75); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 4 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-10-20 (study day 77); relationship: Y; serious criteria: life-threatening
severe
serious
assessed
2026-08-18
Grade 4 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 122); relationship: not assessed; serious criteria: life-threatening
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-22 (study day 202); relationship: N
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.